Galapagos delivers validated oncology targets to Janssen
(Thomson Reuters ONE) -
Mechelen, Belgium; 20 April 2011 - Galapagos NV (Euronext: GLPG) announced today
that its BioFocus service division has delivered a panel of validated oncology
targets in its collaboration with Janssen Research & Development, a division of
Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full
rights to discover, develop and commercialize novel medicines on these targets.
In January 2008, BioFocus entered into a fee-for-service target discovery
collaboration with Janssen, under which BioFocus developed assays in cancer
cells, and discovered and validated novel targets. In January 2010, BioFocus
received a target acceptance payment from Janssen for identifying and validating
drug targets. BioFocus has now confirmed the activity of a panel of targets
across several key pathways in oncology, per contractually defined criteria.
BioFocus may receive success-based payments should certain downstream criteria
be reached by Janssen.
"We continue to see strong demand for our target discovery capabilities and this
collaboration is an example of how we deliver novelty to pharmaceutical
pipelines," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
About BioFocus
BioFocus aims to expand its partners' drug pipelines by accelerating the gene-
to-drug candidate discovery process. This is achieved through a comprehensive
discovery platform, which includes target discovery in human primary cells,
focused as well as diverse compound libraries, in vitro and cell-based
screening, structural biology, medicinal chemistry, ADME/PK services, supported
by unique chemogenomic and informatics tools, and compound library acquisition,
storage and distribution services. As a service division of Galapagos, BioFocus
has 245 employees in four countries worldwide. More info at: www.biofocus.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with six programs in development and over 50
discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline,
Eli Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to
receive up to ?2.5 billion in downstream milestones, plus royalties. The
Galapagos Group has over 800 employees and operates facilities in seven
countries, with global headquarters in Mechelen, Belgium. More info at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1507938]
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 53738
Anzahl Zeichen: 4981
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos delivers validated oncology targets to Janssen"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
